It is currently Sun Mar 29, 2015 6:27 pm

News News of Drug Pipeline

Site map of Drug Pipeline » Forum : Drug Pipeline

A board to discuss future MS therapies in early stage (Phase I or II) trials.

Vaccine

Dignan,

A T cell vaccine (like Tovaxin) being trialled in Israel. Lokks like reults might be out in a few months.


http://c.moreover.com/click/here.pl?j490577852&w=464753

Ian
Read more : Vaccine | Views : 1682 | Replies : 3


Sativex - not much use for spasticity

GW Pharma slumped today after the maker of cannabis medicines revealed some disappointing results from a recent Sativex study.
The company reported that results from Phase III studies into the cannabis-based medicine Sativex failed to reach statistical significance.

The trial was supposed to identify whether Sativex could be used to treat the relief of spasticity in people with Multiple Sclerosis.

"Analysis of the Intention to Treat population - incorporating all patients regardless of whether they ...
Read more : Sativex - not much use for spasticity | Views : 1240 | Replies : 0


FTY720

FTY720 is seen by some as being the 'gold standard' for MS treatment in the future. Unfortunately, approval unlikely until 2010.

In recognition of my sterling efforts this week Arron has kindly offered me two free weeks at his villa in California. Many thanks Arron I'll keep the good work up.

Ian



Novartis: FTY720 offers gold standard MS potential 16 March 2006

Novartis drug to become preferred front-line agent for the treatment of multiple sclerosis. ...
Read more : FTY720 | Views : 1960 | Replies : 4


Overview of drugs

Nothing new but a summary of what's available / in the pipeline.

http://c.moreover.com/click/here.pl?j486543664&w=464753
Read more : Overview of drugs | Views : 1414 | Replies : 0


exosomes

Dignan,

Probably shouldn't go on the list as its only a possibility that it might be beneficial for MS.


http://c.moreover.com/click/here.pl?j486821238&w=464753
Read more : exosomes | Views : 1239 | Replies : 1


MBP8298 For RRMS

BioMS Plans Relapsing-Remitting Multiple Sclerosis Trial

- MBP8298 to be tested in a second major MS patient population -

EDMONTON, Alberta, March 13, 2006 – BioMS Medical Corp (TSX: MS), a leading developer in the treatment of multiple sclerosis (MS), today announced that it is expanding the clinical development program for its lead drug candidate MBP8298. The drug is currently undergoing an international pivotal phase II/III clinical trial with secondary progressive MS patients (SPMS). BioMS ...
Read more : MBP8298 For RRMS | Views : 1386 | Replies : 1


Gemacbio

I think the following is old news. Unfortunately, no details about how effective the treatment is - but I like the three pronged approach. It's very safe (but so is eating spinach)!

http://c.moreover.com/click/here.pl?j485748659&w=464753
Read more : Gemacbio | Views : 1199 | Replies : 0


Tovaxin Update/Trial

This from BBC news.


MS vaccine testing to start in US

Researchers are working towards having an MS vaccine
A US company is set to begin a trial of a vaccine which it claims halts the progress of multiple sclerosis.

PharmaFrontiers is to test its tailor-made vaccine on 100 patients with MS, after a small-scale study showed promise, New Scientist reports.

MS experts have welcomed the research but urged caution because other vaccines have not ...
Read more : Tovaxin Update/Trial | Views : 1641 | Replies : 3


The pharma industry

I read postings on this forum on a regular basis and quite often it amases me. We all have an awful disease and it is a rough ride. But i think we are very quick to judge..

common themes include

Anti - CRABS (well I'm on copaxone and doing great - I know its not for everyone, but I cant be the only one who is doing well on it? OK so its not a ...
Read more : The pharma industry | Views : 2602 | Replies : 12


Generic interferons

Not that anybody is excited about interferons, but if they must be taken at least they might be about to get cheaper...



Ratiopharm: competes with Stada, Sandoz on biogeneric drugs

Mar 8, 2006 - Marketwatch - German generic drug maker Ratiopharm GmbH Wednesday said it is competing with German generics company Stada AG and Novartis AG's generic subsidiary Sandoz in the race for biogeneric drugs to be approved in Europe.

Although the company, which had ...
Read more : Generic interferons | Views : 1335 | Replies : 0


 

Login  •  Register


Statistics

Total posts 224397 • Total topics 23431 • Total members 14842


Contact us | Terms of Service